RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on aesthetics and orthopedics. They develop autologous cell therapies to treat conditions like aging or sun-damaged skin, hair loss, and tendon degeneration. Their next-generation dermal injection technology aims to revolutionize aesthetic treatment outcomes, and they operate through a network of strategic partners and contract research organizations worldwide.
Industries
Nr. of Employees
small (1-50)
RepliCel Life Sciences
Vancouver, British Columbia, Canada, North America
Products
Cell therapy for pattern baldness (RCH-01)
An autologous cell therapy derived from hair-follicle cell populations intended to restore hair growth in androgenetic alopecia; advanced through safety and dose-finding studies and in pivotal efficacy testing.
Cell therapy for aging and sun-damaged skin (RCS-01)
An autologous cell therapy intended to rejuvenate aging or UV-damaged skin by restoring collagen-based extracellular matrix under the dermis.
Cell therapy for tendon degeneration (RCT-01)
An autologous cell therapy derived from skin/hair-follicle cells developed to treat chronic tendinopathy and tendon degeneration in various anatomic sites.
Next-generation precision dermal injection device
An electronic injector designed to provide controlled intradermal and subcutaneous delivery with precise control over depth, dose and pressure, capable of injecting highly viscous products and including features to reduce patient discomfort.
Cell therapy for pattern baldness (RCH-01)
An autologous cell therapy derived from hair-follicle cell populations intended to restore hair growth in androgenetic alopecia; advanced through safety and dose-finding studies and in pivotal efficacy testing.
Cell therapy for aging and sun-damaged skin (RCS-01)
An autologous cell therapy intended to rejuvenate aging or UV-damaged skin by restoring collagen-based extracellular matrix under the dermis.
Cell therapy for tendon degeneration (RCT-01)
An autologous cell therapy derived from skin/hair-follicle cells developed to treat chronic tendinopathy and tendon degeneration in various anatomic sites.
Next-generation precision dermal injection device
An electronic injector designed to provide controlled intradermal and subcutaneous delivery with precise control over depth, dose and pressure, capable of injecting highly viscous products and including features to reduce patient discomfort.
Services
Licensing and regional commercialization partnerships
Structuring and executing exclusive regional licenses and commercialization agreements for cell therapy products and injection devices.
Contract research, development and manufacturing partnerships
Coordination with CROs and CDMOs for clinical research, process development, and technology transfer to support manufacturing scale-up.
Clinical development and trial execution support
Design and oversight of clinical studies including randomized, placebo-controlled phase I trials and progression to pivotal studies across multiple jurisdictions.
Technology transfer and commercialization consulting
Transfer of proprietary processes and device technologies to contract manufacturers and support for partner-led commercialization efforts.
Licensing and regional commercialization partnerships
Structuring and executing exclusive regional licenses and commercialization agreements for cell therapy products and injection devices.
Contract research, development and manufacturing partnerships
Coordination with CROs and CDMOs for clinical research, process development, and technology transfer to support manufacturing scale-up.
Clinical development and trial execution support
Design and oversight of clinical studies including randomized, placebo-controlled phase I trials and progression to pivotal studies across multiple jurisdictions.
Technology transfer and commercialization consulting
Transfer of proprietary processes and device technologies to contract manufacturers and support for partner-led commercialization efforts.
Expertise Areas
- Autologous cell therapy development
- Primary cell isolation and expansion
- Clinical trial management (Phase I to pivotal)
- Dermal and subcutaneous injection systems
Key Technologies
- Autologous cell therapy from hair follicles
- Primary cell culture and expansion
- Precision-controlled dermal/subcutaneous injection systems
- Injection parameter control (depth, dose, pressure)